SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL)
Clinical trials for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL) explained in plain language.
Never miss a new study
Get alerted when new SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL) trials appear
Sign up with your email to follow new studies for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early trial tests new hope for Tough-to-Treat brain cancers
Disease control Recruiting nowThis early-stage study is testing whether combining two drugs, epcoritamab and ibrutinib, is safe for people with lymphoma that has returned in or spread to the brain after prior treatment. The main goal is to find a dose that causes few or manageable side effects. It will includ…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL)
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug trial offers hope for Tough-to-Treat blood cancers
Disease control Recruiting nowThis is a first-in-human study testing a new oral drug called NX-5948 in adults with advanced B-cell blood cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. The study will enroll …
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Four-Drug attack on deadly brain cancer shows promise
Disease control Recruiting nowThis study is testing a combination of four medications for people newly diagnosed with lymphoma in the brain or spinal cord. The treatment aims to control the cancer and keep it from returning by using immunotherapy plus chemotherapy drugs. Researchers will measure how many pati…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC